Fosun Pharma will invest $35m in the generic pharmaceuticals producer, which will invest the cash in developing its product pipeline.
China-based pharmaceutical company Shanghai Fosun Pharmaceuticals agreed to make a $35m equity investment in US-based generic drug manufacturer Amerigen Pharmaceuticals on Friday.
Amerigen comprises a group of companies whose operations span both the US and China, the latter through subsidiary Suzhou Amerigen Pharmaceuticals. It will use the money to expand its product pipeline and increase research and development.
Fosun’s parent company, conglomerate Fosun International, established a $100m venture capital firm in April 2014 called Kinzon Capital in order to…
